Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net income | $8.28M | $120M | $105M | $123M | $119M | $98.8M |
| EPS (diluted) | $0.14 | $1.86 | $1.63 | $1.91 | $1.85 | $1.53 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $89.4M | $266M | -$317M | $219M | -$27.1M | $29.5M |
| Dividends paid | — | $87.8M | $87.8M | $99.4M | $114M | $146M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $81.7M | $87.4M | $30.2M | $43.0M | $51.6M | $23.1M |
| Total assets | — | $2.57B | $2.59B | $2.47B | $2.63B | $2.66B |
| Total liabilities | — | $1.47B | $1.48B | $1.34B | $1.49B | $1.55B |
| Long-term debt | — | $1.41B | $1.39B | $1.26B | $1.39B | $1.47B |
| Shareholders' equity | $1.07B | $1.10B | $1.12B | $1.14B | $1.14B | $1.12B |
| Retained earnings | — | — | -$52.1M | -$32.0M | -$19.9M | -$43.8M |
| Shares (wtd avg diluted) | 58.7M | 64.6M | 64.6M | 64.6M | 64.6M | 64.8M |
Every figure is extracted from Bain Capital Specialty Finance, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.